2024-11-29 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

This report analyzes Eli Lilly and Co. (LLY) stock performance, incorporating provided data and external resources.

**1. Performance Relative to S&P 500 (VOO):**

Eli Lilly and Co. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products.

The cumulative return for LLY is 624.48%, significantly outperforming the S&P 500's cumulative return of 128.86%.  The difference is 495.6%, placing it at the 73.7th percentile of its historical performance range relative to the S&P 500 (max difference: 681.7%, min difference: -24.6%).  This indicates strong outperformance over the observed period.  The provided CAGR data further supports this, consistently showing higher returns than implied by the beta, indicating positive alpha.

**2. Recent Price Movement:**

* **Closing Price:** $788.19 (Last Market: $788.61)
* **5-Day Moving Average:** $766.09
* **20-Day Moving Average:** $784.39
* **60-Day Moving Average:** $865.17

The price is currently below its 20-day and 60-day moving averages, suggesting a potential short-term downtrend.  The difference between the closing price and last market price is minimal, suggesting no significant immediate price fluctuation.

**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 48.13 – Suggests the stock is neither overbought nor oversold, indicating a neutral to slightly bearish sentiment.
* **PPO (Percentage Price Oscillator):** 0.47 – A positive value indicates upward momentum, though relatively weak.
* **Recent Relative Divergence:** -9.0% – Indicates a recent short-term downward trend relative to the S&P 500.
* **Expected Return:** 578.1% – This represents a significant projected long-term (2+ years) outperformance relative to the S&P 500, assuming continued strong performance.  This is a high projection and should be considered cautiously.  The 788.61 price does not reflect an extreme price movement (sudden surge or plunge).


**4. Recent Financial Performance:**

The provided EPS and revenue data show some volatility.  While recent quarters show strong revenue figures, EPS has shown significant swings, including a negative EPS in 2023-11-02 and 2024-10-30.  A more in-depth analysis is needed, including comparison to analyst estimates, to fully evaluate these results.  The last reported earnings ($1.08 EPS, $11.44B revenue) need to be compared to analyst expectations to determine if it beat or missed expectations.  This data is incomplete without further context.


**6. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue remains consistently high. Profit margins are consistently high (80%+), suggesting strong profitability.
* **Capital and Profitability:** Equity has generally increased, though ROE shows significant variability, including a negative value in Q3 2023. This variability requires further investigation into the underlying causes.


**7. News and Recent Issues:**

*(This section requires access to real-time news sources like Finbold, Seeking Alpha, and company press releases to accurately reflect recent news, analyst opinions, and market outlook within the last two days. Please provide the date for a current analysis.)*  A search for recent earnings news and analyst ratings is necessary to fill this section.

**8. Summary:**

LLY has demonstrated significant outperformance relative to the S&P 500 over the provided time frame.  While recent short-term indicators show a slight bearish trend, the long-term outlook remains positive based on the historical data and projected return. However, the recent EPS volatility and variable ROE require careful consideration.  Further analysis is needed to assess the impact of recent earnings reports against expectations and to understand the fluctuations in ROE.  Up-to-date news and analyst opinions are crucial for a complete evaluation.


**9. Disclaimer:** This analysis is based on the limited data provided and publicly available information. It should not be considered financial advice.  Investing in the stock market involves risk, and past performance is not indicative of future results.  Conduct thorough independent research before making any investment decisions.
